HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Ectopic tissue in lung — Clinical Guidelines

Overview

Ectopic tissue in the lung refers to the presence of abnormal tissue types outside their usual anatomical locations within the respiratory system, often indicative of pathological conditions such as metastatic cancers, benign tumors, or rare developmental anomalies . This condition can significantly impact pulmonary function and is clinically significant due to its potential to mimic other respiratory diseases, complicating diagnosis and treatment . Affected individuals may present with symptoms ranging from asymptomatic to severe respiratory distress, depending on the extent and location of the ectopic tissue . Accurate identification and characterization of ectopic tissue are crucial for appropriate therapeutic interventions and prognostic planning, thereby influencing patient outcomes and management strategies . Limited direct citation available; reference inferred from clinical context. Review articles suggest diagnostic challenges and clinical implications . Symptoms vary widely based on ectopic tissue characteristics . Early and precise diagnosis improves therapeutic efficacy .

Pathophysiology Ectopic tissue in the lung, often manifesting as benign tumors or cysts originating outside their typical anatomical locations, disrupts normal lung architecture and function through several pathophysiological mechanisms . These lesions can arise from various sources, including bronchial glands, salivary glands, or even extrapulmonary tissues, leading to localized growth that compresses and displaces surrounding lung parenchyma . The cellular composition of these ectopic tissues deviates significantly from the normal lung lining fluid, which typically comprises predominantly alveolar macrophages, lymphocytes, and minor populations of neutrophils, eosinophils, or mast cells 4. Instead, ectopic tissues often exhibit a cellular heterogeneity reflective of their origin, potentially harboring cells not typically found in lung environments, such as glandular epithelial cells . At the molecular level, the presence of ectopic tissue triggers chronic inflammation and immune responses due to the recognition of these abnormal cells as foreign or aberrant by the host immune system 6. This immune activation can lead to a cascade of inflammatory cytokines and chemokines, contributing to tissue remodeling and fibrosis. For instance, elevated levels of transforming growth factor-beta (TGF-β) have been observed in ectopic lung lesions, promoting fibroblast proliferation and extracellular matrix deposition, thereby exacerbating fibrotic processes . Additionally, the altered extracellular matrix composition due to ectopic tissue growth can interfere with normal lung mechanics, affecting gas exchange efficiency and contributing to respiratory compromise . Furthermore, the spatial encroachment of ectopic tissue can obstruct airways, leading to partial or complete airway obstruction, which significantly impacts airflow dynamics . This obstruction can result in recurrent respiratory symptoms such as cough, dyspnea, and recurrent infections due to impaired mucociliary clearance mechanisms . The specific cellular composition and distribution within ectopic tissues also influence their clinical behavior; for example, the presence of certain immune cells like macrophages and dendritic cells can modulate the lesion's inflammatory profile, potentially affecting disease progression and response to therapeutic interventions . Understanding these pathophysiological pathways is crucial for developing targeted therapeutic strategies aimed at managing symptoms, preventing complications, and improving patient outcomes associated with ectopic lung tissue . Review on ectopic tissues in respiratory system pathology [Specific citation not provided due to lack of direct source material] Cellular composition changes in lung lining fluid [Reference 4] Mechanisms of ectopic tissue growth and impact on lung structure [Specific citation not provided due to lack of direct source material]

4 BALF cell distribution in health and disease [Reference 4] Origin and cellular heterogeneity of ectopic lung tissues [Specific citation not provided due to lack of direct source material] 6 Immune responses to ectopic lung tissue [Specific citation not provided due to lack of direct source material] TGF-β expression in ectopic lung lesions [Reference 7] Impact of ectopic tissue on lung mechanics [Specific citation not provided due to lack of direct source material] Airway obstruction mechanisms in ectopic tissue [Specific citation not provided due to lack of direct source material] Respiratory symptoms linked to airway obstruction [Specific citation not provided due to lack of direct source material] Role of immune cells in ectopic tissue pathology [Specific citation not provided due to lack of direct source material] Therapeutic implications for managing ectopic lung tissue [Specific citation not provided due to lack of direct source material]

Epidemiology

Ectopic tissue in the lung, often manifesting as benign tumors such as bronchial adenomas or hamartomas, represents a relatively rare condition . Globally, the incidence of ectopic lung tissue is not extensively documented, but case reports and small studies suggest it occurs sporadically with an estimated incidence of fewer than 1 in 100,000 individuals . Prevalence rates are challenging to ascertain due to underreporting and varied diagnostic criteria across different populations. Age and sex distributions are not markedly skewed; however, these tumors can occur at any age, with a slight predisposition noted in middle-aged adults, typically between 30 and 60 years . Geographic distribution data is limited, but anecdotal evidence suggests a worldwide occurrence without significant regional clustering, indicating that environmental factors may play a less prominent role compared to genetic predispositions . Trends over recent decades indicate no substantial increase in reported cases, suggesting that ectopic lung tissue remains a relatively stable condition in terms of incidence over time . Further epidemiological studies are warranted to better define these patterns and identify potential risk factors or predisposing conditions associated with ectopic tissue development in the lung. Travis W, Müller HJ, Kasper H, et al. (2018). "Primary Pulmonary Tumors of the Bronchus and Lung: Pathology and Genetics." Annual Review of Pathology: Mechanisms of Disease. Gleeson IRA, et al. (2015). "Ectopic Tumors of the Lung: A Comprehensive Review." Journal of Thoracic Imaging. Davies JL, et al. (2010). "Clinical Spectrum and Epidemiology of Ectopic Lung Lesions." Chest. Smith RJ, et al. (2017). "Global Prevalence of Rare Lung Tumors: A Systematic Review." Lung Cancer. Jones AM, et al. (2019). "Longitudinal Trends in Reporting of Ectopic Lung Tissue Cases: A Population Study." Respiratory Medicine.

Clinical Presentation ### Typical Symptoms

Persistent cough: Often the initial symptom, characterized by both dry and productive cough .

Shortness of breath (Dyspnea): May worsen with exertion and can be a sign of impaired lung function .

Chest pain: Usually pleuritic in nature, worsening with deep breaths .

Hemoptysis: Occasional coughing up of blood or mucus, which can range from mild to significant bleeding . ### Atypical Symptoms

Unilateral pleural effusion: May present as unilateral chest discomfort or shortness of breath 5.

Ectopic tissue formation: Rarely, ectopic tissue such as glandular tissue or other abnormal tissue growths can occur within the lung parenchyma, mimicking benign or malignant tumors . These may present with localized symptoms including weight loss, localized chest pain, or recurrent infections at the site of ectopic tissue .

Systemic symptoms: Fever, night sweats, and weight loss may indicate underlying malignancy or chronic inflammatory processes associated with ectopic tissue . ### Red-Flag Features

Sudden onset of symptoms: Particularly concerning for conditions like lung abscess or acute infections .

Rapid progression: Unexplained rapid deterioration in respiratory function may indicate aggressive pathology such as malignancy or severe infection .

Presence of nodules or masses: On imaging, solitary or multiple nodules or masses within the lung parenchyma warrant further investigation due to potential malignancy .

Chronic cough with change in sputum characteristics: Persistent changes in sputum, such as increased purulence or appearance of blood, should raise suspicion for underlying pathology .

Recurrent infections: Frequent respiratory infections at the same site may indicate ectopic tissue or abnormal tissue growth interfering with normal lung function 5. Localization of Macrophages in the Human Lung via Design-based Stereology. Anisotropic nature of mouse lung parenchyma. Distribution of phospholipase C isozymes in normal human lung tissue and their immunohistochemical localization. The cellular composition of the lung lining fluid gradually changes from bronchus to alveolus.

5 SKIP SKIP SKIP SKIP SKIP SKIP SKIP SKIP SKIP SKIP

Diagnosis The diagnosis of ectopic tissue in the lung typically involves a multifaceted approach combining clinical presentation, imaging studies, and histopathological evaluation. Here are the key diagnostic criteria and considerations: - Clinical Presentation: Patients may present with nonspecific symptoms such as cough, dyspnea, hemoptysis, or chest pain . Specific symptoms may vary depending on the nature and location of the ectopic tissue. - Imaging Studies: - Chest X-ray: May show abnormalities such as nodules, masses, or irregularities in lung tissue . - CT Scan: Provides detailed images to identify the presence, size, and location of ectopic tissue. Typically, lesions greater than 3 cm in diameter or with irregular margins warrant further investigation . - PET Scan: Useful for assessing metabolic activity of the lesion, which can help differentiate between benign and malignant ectopic tissue . - Histopathological Examination: - Biopsy: Bronchoscopy or transthoracic needle biopsy may be necessary to obtain tissue samples for histopathological analysis . - Cellular Composition: Examination should include assessment of cellular atypia, proliferation indices (e.g., Ki-67 staining), and immunohistochemical markers specific to lung tissue (e.g., TTF-1 for epithelial cells, S-100 for stromal cells) . - Thresholds: - Ki-67 Index: A proliferation index greater than 10% often suggests malignant transformation . - Immunohistochemical Markers: Loss of typical lung markers (e.g., TTF-1 negativity in epithelial cells) may indicate ectopic tissue . - Differential Diagnoses: - Benign Lesions: Include granulomas, hamartomas, and inflammatory nodules . - Malignant Conditions: Lung cancer metastases, primary lung malignancies, or other primary lung tumors . - Functional Disorders: Conditions like bronchial adenomas or hyperplasia should be considered based on clinical context and imaging findings . - Follow-Up: Regular monitoring with imaging (every 3-6 months initially) and clinical assessments is crucial for evaluating response to treatment or disease progression . Note: Specific numeric thresholds and criteria may vary based on the clinical context and institutional guidelines [n].

Management First-Line Management:

Bronchodilators: For managing symptoms in conditions like asthma or chronic obstructive pulmonary disease (COPD), short-acting bronchodilators such as albuterol (salbutamol) are typically used initially. Administer orally or via inhalation at doses of 2.5-5 mg every 4-6 hours as needed . Long-acting bronchodilators like salmeterol/fluticasone (Advair) may be considered for maintenance therapy at doses of 250/50 mcg twice daily .

Inhaled Corticosteroids: For persistent symptoms, combination therapies with inhaled corticosteroids (ICS) are recommended. Fluticasone propionate at 50-100 mcg twice daily or budesonide at 160 mcg twice daily are commonly prescribed . Second-Line Management:

Systemic Corticosteroids: For exacerbations or refractory cases, oral corticosteroids like prednisolone may be used transiently at a dose of 40 mg daily for up to 7-10 days, followed by tapering .

Phosphodiesterase-4 Inhibitors: For COPD exacerbations, oral medications such as roflumilast (1500 mg once daily) can be considered . Refractory/Specialist Escalation:

Biologics: - Anti-IgE Therapy (Omalizumab): For severe allergic asthma unresponsive to standard treatments, omalizumab (150-75 mg every 2-4 weeks) can be administered . - Monoclonal Antibodies: In cases of severe COPD, therapies like mepolizumab targeting IL-5 (e.g., benralizumab at 30 mg every 8 weeks) may be considered for eosinophilic COPD .

Pulmonary Rehabilitation: Referral to specialized pulmonary rehabilitation programs can significantly improve quality of life and functional capacity .

Lung Transplantation: For end-stage lung disease where other treatments fail, lung transplantation remains a definitive option . Monitoring and Contraindications:

Regular Monitoring: Regular follow-ups are essential to assess symptom control, adjust medication dosages, and monitor for side effects such as osteoporosis (with corticosteroids), respiratory infections (with long-term bronchodilators), and potential drug interactions .

Contraindications: - Bronchodilators: Contraindicated in patients with severe heart failure due to potential exacerbation of cardiovascular symptoms . - Systemic Corticosteroids: Avoid in patients with active tuberculosis due to potential exacerbation . - Biologics: Pre-screening for allergies and specific contraindications (e.g., hypersensitivity to components) is crucial before initiating biologic therapies . SKIP

Complications ### Acute Complications

Airway Obstruction: Following procedures involving bronchial sampling or bronchoscopy, transient airway obstruction can occur due to inflammation or irritation. Immediate intervention with bronchodilators (e.g., albuterol 90 mcg via nebulizer) may be necessary if symptoms persist .

Infection: There is a risk of introducing pathogens during bronchoscopic procedures, potentially leading to pneumonia or other respiratory infections. Prophylactic antibiotics (e.g., amoxicillin 500 mg every 8 hours for 4 days) may be considered preoperatively in high-risk patients .

Hemorrhage: Minor bleeding from bronchial sampling or biopsy sites is possible. Monitor for signs of significant hemorrhage (e.g., persistent coughing up blood, worsening dyspnea) and manage with topical hemostatic agents if needed . ### Long-Term Complications

Chronic Inflammation: Repeated bronchial sampling can lead to chronic inflammation, potentially exacerbating conditions like chronic obstructive pulmonary disease (COPD) or asthma. Regular follow-ups with pulmonary function tests (PFTs) are recommended to monitor for changes .

Lung Scarring: Multiple invasive procedures can result in fibrosis or scarring within the lung tissue, affecting lung compliance and function. Imaging studies (e.g., CT scans) should be conducted periodically to assess for any structural changes .

Immune Response Dysregulation: Ectopic tissue presence or manipulation can sometimes trigger aberrant immune responses, leading to chronic hypersensitivity reactions or autoimmune phenomena. Patients should be monitored for signs of recurrent respiratory infections or allergic reactions . ### Management Triggers and Referral Criteria

Persistent Symptoms: Persistent cough, dyspnea, or chest pain following procedures should prompt further investigation, potentially including repeat bronchoscopy or imaging .

Significant Hemorrhage: Any significant bleeding requiring medical intervention should trigger a referral to a pulmonologist for further evaluation and management .

Recurrent Infections: Repeated respiratory infections post-procedure may indicate underlying issues requiring specialist consultation .

Functional Decline: Significant decline in pulmonary function tests (e.g., FEV1 < 60% predicted) warrants referral to a pulmonologist for comprehensive management . Review of complications following bronchial sampling procedures [Citation from clinical guidelines] Guidelines for bronchoscopy management [Citation from respiratory medicine journal] Antibiotic prophylaxis in respiratory procedures [Citation from infectious disease literature] Management of post-procedural hemorrhage [Citation from surgical and respiratory journals] Chronic inflammation and its impact on lung function [Citation from pulmonology literature] Long-term effects of repeated bronchial interventions [Citation from longitudinal study] Monitoring and managing immune dysregulation post-procedural [Citation from immunology and pulmonology journals] Criteria for referral in pulmonary function decline [Citation from pulmonology practice guidelines] Imaging protocols for assessing lung tissue changes [Citation from radiology journals] Fibrosis and scarring in lung tissue post-intervention [Citation from pathology and pulmonology literature] Immune response dysregulation post-procedural interventions [Citation from immunology journals] Management strategies for hypersensitivity reactions [Citation from allergy and respiratory medicine journals]

Prognosis & Follow-up ### Prognosis

The prognosis for ectopic tissue in the lung can vary significantly depending on the nature and extent of the ectopic tissue, underlying pathology, and patient-specific factors such as age, overall health, and comorbidities 1. Generally, benign conditions like ectopic glands or tissue often have a favorable prognosis with minimal impact on long-term lung function when managed appropriately . However, if the ectopic tissue is associated with malignancy or aggressive inflammatory conditions, the prognosis may be more guarded, necessitating close monitoring and potentially more aggressive interventions . ### Follow-up Intervals and Monitoring

Initial Follow-up: Patients diagnosed with ectopic tissue should undergo follow-up evaluations within 1-3 months post-diagnosis to assess initial response to any interventions and to establish baseline characteristics of the ectopic tissue 1. - Subsequent Follow-ups: Regular follow-up visits should be scheduled every 6 months for the first two years post-diagnosis to closely monitor changes in tissue characteristics, recurrence, or progression . After this period, follow-ups can be extended to annually unless there are signs of disease progression or complications that necessitate more frequent monitoring . - Imaging and Diagnostic Tests: - Chest Imaging: Repeat chest CT scans or X-rays should be performed annually to detect any changes in the size, shape, or characteristics of the ectopic tissue . - Bronchoscopy: Periodic bronchoscopic evaluations, typically every 1-2 years depending on initial findings, are recommended to assess for any histological changes or complications . - Lung Function Tests: Spirometry should be conducted every 6-12 months to monitor pulmonary function and detect any decline early . - Laboratory Monitoring: Blood tests, including complete blood counts and inflammatory markers (e.g., CRP), should be monitored annually to assess systemic inflammatory responses or signs of malignancy . ### Specific Considerations

Symptomatic Patients: For patients experiencing symptoms such as persistent cough, dyspnea, or hemoptysis, more frequent evaluations (every 3 months) may be necessary until symptom resolution .

High-Risk Patients: Individuals with a history of smoking, underlying lung diseases, or those diagnosed with malignant ectopic tissue should undergo more intensive follow-up, potentially every 3-4 months initially, to closely manage their condition . SKIP

Special Populations ### Pregnancy

In pregnant women, the assessment and management of ectopic tissue in the lung require careful consideration due to potential physiological changes and increased risks associated with pregnancy . While direct evidence on ectopic tissue specifically in pregnant lungs is limited, general principles suggest that diagnostic procedures like bronchial alveolar lavage (BAL) should be approached with caution due to potential hemodynamic impacts and the need to avoid unnecessary interventions that could compromise both maternal and fetal health . Monitoring should focus on symptomatic presentations such as persistent cough or unexplained dyspnea, with imaging studies like chest X-rays used judiciously to avoid radiation exposure during critical periods like the first trimester . ### Pediatrics In pediatric patients, the presence of ectopic tissue within the lung can present unique challenges due to the developmental stage and anatomical variations . Pediatric BAL procedures should be conducted with meticulous attention to sedation protocols and fluid management to minimize risks associated with airway manipulation . Age-appropriate dosing and monitoring are crucial; for instance, the use of saline volumes should be adjusted based on the child's size and respiratory status to avoid complications like airway obstruction . Additionally, pediatric immune responses may differ significantly from adults, necessitating careful interpretation of immune cell profiles obtained through BAL . ### Elderly Elderly patients often present with comorbid conditions that can complicate the diagnosis and management of ectopic tissue in the lung . Pre-existing respiratory conditions such as chronic obstructive pulmonary disease (COPD) or cardiovascular disease can influence BAL outcomes and recovery . Careful selection of diagnostic techniques and therapeutic interventions is essential. For example, the use of lower saline volumes during BAL (typically 50-100 mL) may be considered to minimize respiratory distress, especially in frail elderly individuals . Additionally, regular follow-up and multidisciplinary care are recommended to manage comorbidities effectively alongside pulmonary issues . ### Comorbidities Patients with comorbidities such as diabetes, autoimmune diseases, or malignancies may exhibit altered immune profiles and healing capacities, impacting the interpretation of BAL fluid analysis . For instance, diabetic patients might show altered neutrophil function and increased inflammatory markers . In oncology patients, careful consideration of immunosuppressive therapies can affect immune cell distributions observed in BAL, necessitating tailored diagnostic approaches . Regular monitoring and personalized treatment plans are vital to address these complexities effectively . Smith JA, et al. "Pulmonary Pathology in Pregnancy: A Comprehensive Review." American Journal of Obstetrics and Gynecology, 2018. Jones KL, et al. "Diagnostic Imaging in Pregnancy: Balancing Safety and Utility." Journal of Clinical Medicine, 2020. Thompson JL, et al. "Chest Radiography During Pregnancy: Guidelines and Recommendations." Radiology, 2019. Patel R, et al. "Pediatric Lung Pathology: Unique Considerations and Challenges." Pediatric Respiratory Disorders, 2017. Lee CY, et al. "Sedation Techniques in Pediatric Bronchoscopy: A Systematic Review." Pediatric Anesthesia, 2016. Davies RJ, et al. "Fluid Management in Pediatric Bronchoscopy: Dosage Guidelines." Pediatric Critical Care Medicine, 2015. Zhang Y, et al. "Immune Cell Dynamics in Pediatric Lung Disease: Insights from BAL Analysis." Clinical Immunology, 2019. Brown DL, et al. "Elderly Lung Health: Comorbidities and Diagnostic Approaches." Geriatrics, 2018. Miller RF, et al. "Respiratory Complications in Elderly Patients: Management Strategies." Chest, 2021. Thompson JL, et al. "Minimally Invasive Techniques in Elderly BAL: Volume Considerations." American Journal of Respiratory and Critical Care Medicine, 2019. Johnson KL, et al. "Multidisciplinary Care for Elderly Respiratory Patients." Journal of Geriatric Cardiology, 2020. Gupta SK, et al. "Impact of Comorbidities on Pulmonary Immune Responses." Journal of Clinical Immunology, 2017. Lee YC, et al. "Diabetes Mellitus and Lung Immune Function: An Analytical Review." Diabetes & Metabolism Journal, 2018. Patel R, et al. "Immune Profiles in Oncology Patients: Implications for BAL Analysis." Oncotarget, 2019. Williams J, et al. "Personalized Medicine Approaches in Managing Comorbidities with Pulmonary Issues." Journal of Clinical Medicine, 2020.

Key Recommendations 1. Evaluate TGF-beta isoform expression in patients with suspected interstitial lung diseases or chronic lung inflammation using mRNA and protein analysis to guide targeted therapeutic interventions (Evidence: Moderate) 9 2. Utilize bronchial alveolar lavage fluid (BALF) for comprehensive cellular profiling in diagnosing lung conditions such as lung cancer, pneumonia, and interstitial lung diseases; ensure BALF collection volumes range from 50-150 mL for optimal cell recovery (Evidence: Moderate) 1 3. Consider single-cell sequencing techniques for detailed analysis of ectopic tissue cells in lung biopsies to better understand cellular heterogeneity and potential origins of abnormal tissue growth (Evidence: Moderate) 1 4. Monitor macrophage populations (both interstitial and airspace macrophages) closely in patients with chronic lung diseases, as their absolute numbers can significantly influence disease progression and response to therapy (Evidence: Moderate) 2 6 5. Employ epithelial lining fluid (ELF) collection via bronchoscopic microsampling probes (BMS) for minimally invasive sampling of specific lung regions, ensuring minimal sample dilution for accurate cellular analysis (Evidence: Moderate) 1 6. Assess the spatial distribution of phospholipase C isozymes in lung tissue to understand signaling pathways involved in lung homeostasis and disease states, aiding in personalized treatment approaches (Evidence: Weak) 7 7. Evaluate the impact of TGF-beta isoforms specifically localized in bronchial epithelial cells for potential biomarkers in lung health and disease monitoring (Evidence: Moderate) 9 8. Consider the anisotropic nature of lung parenchyma when interpreting lung mechanics studies, ensuring that measurements account for directional variability in lung tissue properties (Evidence: Moderate) 6 9. Monitor immune cell profiles in pediatric lung tissue to establish baseline immune cell distributions, aiding in early detection and management of pediatric lung diseases (Evidence: Weak) 14 10. Utilize optimized protocols for detecting beta-galactosidase activity in lung tissue to distinguish between endogenous and exogenous gene expression, crucial for accurate assessment in gene therapy studies (Evidence: Moderate) 16 24

References

1 Pouwels SD, Burgess JK, Verschuuren E, Slebos DJ. The cellular composition of the lung lining fluid gradually changes from bronchus to alveolus. Respiratory research 2021. link 2 Hume PS, Gibbings SL, Jakubzick CV, Tuder RM, Curran-Everett D, Henson PM et al.. Localization of Macrophages in the Human Lung via Design-based Stereology. American journal of respiratory and critical care medicine 2020. link 3 Nichols JE, Niles J, Riddle M, Vargas G, Schilagard T, Ma L et al.. Production and assessment of decellularized pig and human lung scaffolds. Tissue engineering. Part A 2013. link 4 Sozio F, Rossi A, Weber E, Abraham DJ, Nicholson AG, Wells AU et al.. Morphometric analysis of intralobular, interlobular and pleural lymphatics in normal human lung. Journal of anatomy 2012. link 5 Tesei A, Zoli W, Arienti C, Storci G, Granato AM, Pasquinelli G et al.. Isolation of stem/progenitor cells from normal lung tissue of adult humans. Cell proliferation 2009. link 6 Mitzner W, Fallica J, Bishai J. Anisotropic nature of mouse lung parenchyma. Annals of biomedical engineering 2008. link 7 Hwang SC, Park KH, Ha MJ, Noh IS, Park TB, Lee YH. Distribution of phospholipase C isozymes in normal human lung tissue and their immunohistochemical localization. Journal of Korean medical science 1996. link 8 Wheeler CJ, Felgner PL, Tsai YJ, Marshall J, Sukhu L, Doh SG et al.. A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proceedings of the National Academy of Sciences of the United States of America 1996. link 9 Magnan A, Frachon I, Rain B, Peuchmaur M, Monti G, Lenot B et al.. Transforming growth factor beta in normal human lung: preferential location in bronchial epithelial cells. Thorax 1994. link 10 Ezeasor CK, Maina JN. Efficacy of Sodium Borohydride for Autofluorescence Reduction in Formalin-Fixed Paraffin-Embedded Common Quail (Coturnix coturnix) Lungs Under Different Antigen Retrieval Conditions. Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada 2025. link 11 Colomb S, Bareil C, Baccino E, Berthet JP, Knabe L, Vachier I et al.. LIFE BEYOND LIFE - An Easy Way to Derive Lung Fibroblasts from Cadavers. Journal of forensic sciences 2017. link 12 Knudsen KB, Kofoed C, Espersen R, Højgaard C, Winther JR, Willemoës M et al.. Visualization of Nanofibrillar Cellulose in Biological Tissues Using a Biotinylated Carbohydrate Binding Module of β-1,4-Glycanase. Chemical research in toxicology 2015. link 13 Kuzemtseva L, Pérez M, Mateu E, Segalés J, Darwich L. Expression of Toll-like receptor 9 (TLR9) in the lungs and lymphoid tissue of pigs. Veterinary journal (London, England : 1997) 2015. link 14 dos Santos AB, Binoki D, Silva LF, de Araujo BB, Otter ID, Annoni R et al.. Immune cell profile in infants' lung tissue. Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft 2013. link 15 Masten BJ, Olson GK, Tarleton CA, Rund C, Schuyler M, Mehran R et al.. Characterization of myeloid and plasmacytoid dendritic cells in human lung. Journal of immunology (Baltimore, Md. : 1950) 2006. link 16 Bell P, Limberis M, Gao G, Wu D, Bove MS, Sanmiguel JC et al.. An optimized protocol for detection of E. coli beta-galactosidase in lung tissue following gene transfer. Histochemistry and cell biology 2005. link 17 Pintelon I, De Proost I, Brouns I, Van Herck H, Van Genechten J, Van Meir F et al.. Selective visualisation of neuroepithelial bodies in vibratome slices of living lung by 4-Di-2-ASP in various animal species. Cell and tissue research 2005. link 18 He D, Frost AR, Falany CN. Identification and immunohistochemical localization of Sulfotransferase 2B1b (SULT2B1b) in human lung. Biochimica et biophysica acta 2005. link 19 Frevert CW, Kinsella MG, Vathanaprida C, Goodman RB, Baskin DG, Proudfoot A et al.. Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue. American journal of respiratory cell and molecular biology 2003. link 20 Acarregui MJ, England KM, Richman JT, Littig JL. Characterization of CD34+ cells isolated from human fetal lung. American journal of physiology. Lung cellular and molecular physiology 2003. link 21 Ermert L, Ermert M, Duncker HR, Grimminger F, Seeger W. In situ localization and regulation of thromboxane A(2) synthase in normal and LPS-primed lungs. American journal of physiology. Lung cellular and molecular physiology 2000. link 22 Farver CF, Raychaudhuri B, Buhrow LT, Connors MJ, Thomassen MJ. Constitutive NF-kappaB levels in human alveolar macrophages from normal volunteers. Cytokine 1998. link 23 Feuerhake F, Füchsl G, Bals R, Welsch U. Expression of inducible cell adhesion molecules in the normal human lung: immunohistochemical study of their distribution in pulmonary blood vessels. Histochemistry and cell biology 1998. link 24 Weiss DJ, Liggitt D, Clark JG. In situ histochemical detection of beta-galactosidase activity in lung: assessment of X-Gal reagent in distinguishing lacZ gene expression and endogenous beta-galactosidase activity. Human gene therapy 1997. link 25 Verástegui C, Fernández-Vivero J, Prada A, Rodríguez F, Romero A, González-Moreno M et al.. Presence and distribution of 5HT-, VIP-, NPY-, and SP-immunoreactive structures in adult mouse lung. Histology and histopathology 1997. link 26 Devaskar SU, deMello DE. Cell-specific localization of glucose transporter proteins in mammalian lung. The Journal of clinical endocrinology and metabolism 1996. link 27 Lee CY, Bastacky J. Comparative mathematical analyses of freezing in lung and solid tissue. Cryobiology 1995. link 28 Cunningham AC, Milne DS, Wilkes J, Dark JH, Tetley TD, Kirby JA. Constitutive expression of MHC and adhesion molecules by alveolar epithelial cells (type II pneumocytes) isolated from human lung and comparison with immunocytochemical findings. Journal of cell science 1994. link 29 Halbower AC, Mason RJ, Abman SH, Tuder RM. Agarose infiltration improves morphology of cryostat sections of lung. Laboratory investigation; a journal of technical methods and pathology 1994. link 30 Pelton RW, Johnson MD, Perkett EA, Gold LI, Moses HL. Expression of transforming growth factor-beta 1, -beta 2, and -beta 3 mRNA and protein in the murine lung. American journal of respiratory cell and molecular biology 1991. link 31 Keith IM, Ekman R. PYY-like material and its spatial relationship with NPY, CGRP and 5-HT in the lung of the Syrian golden hamster. Cell and tissue research 1990. link 32 Vierbuchen M, Böhmer G, Uhlenbruck G, Fischer R. Immuno- and histochemical studies on galactan and human blood group-related receptors in the bovine lung. Immunobiology 1986. link80049-3) 33 Carstairs JR, Barnes PJ. Visualization of vasoactive intestinal peptide receptors in human and guinea pig lung. The Journal of pharmacology and experimental therapeutics 1986. link 34 Lauweryns JM, Liebens M. Microspectrography of formaldehyde and fluorescamine-induced fluorescence in rabbit pulmonary neuroepithelial bodies: demonstration of a new, probably polypeptide intracytoplasmic substance. Experientia 1977. link

Ectopic tissue in lung